Setup. Ionis runs the antisense oligonucleotide platform. Q1 2026 10-Q filed April 29; GSK confirmed bepirovirsen's Breakthrough Therapy Designation the day before. Two disclosures landed inside the five-day window when sell-side last updated ratings.

What the filing says. Three FDA decisions stack between June 30 and October 26, 2026.

• Olezarsen for severe hypertriglyceridemia, PDUFA June 30. Same molecule as already-approved TRYNGOLZA for FCS; sHTG TAM is 3M+ patients vs ≈3,000 for FCS. Phase 3 CORE/CORE2/ESSENCE all positive. BTD + Priority Review. Q1 dev spend -49% YoY consistent with NDA in review.
• Zilganersen for Alexander disease, PDUFA September 22. Phase 1-3 met primary endpoint (10MWT gait speed +33.3% LSM diff vs control, p=0.041). BTD + Priority Review + Orphan + Rare Pediatric Disease (PRV-eligible).
• Bepirovirsen for chronic hepatitis B (GSK-partnered), PDUFA October 26. B-Well 1 and B-Well 2 Phase 3 both met primary endpoint for functional cure. GSK confirmed BTD grant April 28 — additive to prior Fast Track and Priority Review. Five concurrent regulatory tracks (US, EU, Japan, China, Canada). IONS receives 10-12% royalty plus $35M milestone on first ex-China approval.

Q1 revenue $246M (+87% YoY) is partially headline-flattering: $95M was non-recurring milestones ($50M Roche AD Phase 1 initiation, $30M GSK EU/Japan filings, $15M Otsuka EU approval). Normalized run-rate ≈$151M. FY25's $943.7M baseline included a $280M Ono Pharmaceutical one-time that does not recur.

The Roche pipeline disclosure (April 23-24) names RG6627 (RO7812653), an APOE-targeting intrathecal ASO in Phase 1 for Alzheimer's disease (NCT07234942, SAD, N=38), explicitly "in collaboration with Ionis." Distinct from RG6042/tominersen for Huntington's. APOE is the strongest validated AD genetic risk factor. Phase 2 milestone next: $10M.

TRYNGOLZA Q1 sales $27.1M (+330% YoY); DAWNZERA $15.9M first full quarter — independent commercial capability operating. SG&A doubled to $150M (+97% YoY) with guidance for further increases. Pro-forma cash $1.69B post-April convertible payoff.

What the market thinks. Up +135% over the past year. Sell-side mean target $98.61, median $104, MS at $130. June ATM IV 44.8% (11th percentile of 52-week range). Implied straddle move ±18% by June expiry. Aggregate target implies +32% upside.

Why the gap exists. Aggregate direction is approximately priced. The gap is in two specific inputs and one revenue-shape misread.

1. Bepirovirsen BTD timing. Sell-side ratings dated April 21-30 largely predate the April 28 BTD grant. Base-rate P(approval) shifts from ≈54% (all BTD-designated) toward ≈70-80% (BTD-submitted BLA/NDA with two confirmatory Phase 3 wins, no approved competitor for CHB functional cure). The royalty stream on a 250M-patient TAM is material to 2027+ revenue and not in models built before April 28.
2. Roche APOE-AD ASO. The pipeline disclosure sits in Roche's Q1 document, which IONS-coverage analysts do not ordinarily parse. APOE × AD × Roche × ASO is four-way validation. Phase 1 just initiated.
3. Revenue trajectory. Consensus may anchor to the +87% Q1 headline. With $95M of one-time Q1 milestones and the $280M FY25 Ono baseline, FY26 likely prints below $943.7M even with three approvals — Q2 will look down sequentially even if olezarsen approves on time.

Risks (ranked by impact).

1. Olezarsen CRL (P 8-15%) — single largest shock state; estimated -20% to -25%. Pipeline holds.
2. SG&A trajectory — guidance for continued increases puts annualized run-rate at $600M+; severe drag if launches disappoint.
3. IONS-specific tariff quantification materially worse than ALNY/BIIB peer cohort — reframes from cohort-norm (LR ≈0.95) to idio bear.
4. Bepirovirsen CRL (P 20-30%) — manageable; royalty deferred not destroyed.
5. SPINRAZA decline accelerates beyond -15% YoY — partially offset by BIIB high-dose label (March 2026) and ThecaFlex implantable port.

Catalysts.

• June 30, 2026 — Olezarsen sHTG PDUFA
• Early August 2026 — Q2 earnings (olezarsen launch trajectory)
• September 22, 2026 — Zilganersen AxD PDUFA
• October 26, 2026 — Bepirovirsen HBV PDUFA
• Early November 2026 — Q3 earnings (three-approval trajectory; tariff cohort discriminator)
• AAIC July 2026 or AD/PD March 2027 — Possible Roche RG6627 Phase 1 data

What would change our mind.

• Olezarsen AdCom announced — increases uncertainty premium, suggests label-narrowing concern
• Olezarsen + zilganersen both CRL — pipeline thesis broken
• IONS tariff quantification materially exceeds peer cohort — flips from sector-priced to idio bear
• Roche removing RG6627 from a future pipeline disclosure — removes the optionality kicker
• Sell-side mean target converging $115+ pre-PDUFA — distribution priced

Evidence